BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38049717)

  • 1. Threshold growth has a limited role in differentiating hepatocellular carcinoma from other focal hepatic lesions.
    Lyu R; Wang D; Hu W; Gao Z; Yu C; Wang J; Li M; Jia K
    BMC Med Imaging; 2023 Dec; 23(1):201. PubMed ID: 38049717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
    Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
    Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.
    Zhang ZX; Xv H; Du YN; Lv ZB; Yang ZH
    BMC Gastroenterol; 2024 Mar; 24(1):117. PubMed ID: 38515017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
    Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 11. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
    Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
    Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
    Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
    Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
    Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
    Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.